Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

The Evolving War on Cancer

(2011) Daniel A. Haber et al.   CELL

Searching for synthetic lethality in cancer

(2011) Rachel Brough et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Cancer genomics: from discovery science to personalized medicine

(2011) Lynda Chin et al.   NATURE MEDICINE

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability

(2011) A. Aly et al.   Journal of Molecular Cell Biology

Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”

(2010) Sreenath V. Sharma et al.   BIOCHEMICAL PHARMACOLOGY

Targeting BRAF for patients with melanoma

(2010) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

(2010) David E. Gerber et al.   CANCER CELL

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

(2010) Kavya Rakhra et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib

(2010) F Stegmeier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs

(2010) Vladimir Krystof et al.   CURRENT DRUG TARGETS

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

(2010) Sebastian M.B. Nijman   FEBS LETTERS

Clinical Implications of the Cancer Genome

(2010) Laura E. MacConaill et al.   JOURNAL OF CLINICAL ONCOLOGY

The GIST paradigm: lessons for other kinase-driven cancers

(2010) Cristina R Antonescu   JOURNAL OF PATHOLOGY

Translating cancer research into targeted therapeutics

(2010) J. S. de Bono et al.   NATURE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies

(2009) Jaclyn A. Freudenberg et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

A comprehensive catalogue of somatic mutations from a human cancer genome

(2009) Erin D. Pleasance et al.   NATURE

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Shifting paradigms: the seeds of oncogene addiction

(2009) Charles L Sawyers   NATURE MEDICINE

Attacking cancer at its foundation

(2009) Nicholas Lydon   NATURE MEDICINE

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

(2009) A. Bertotti et al.   Science Signaling

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Defining the blueprint of the cancer genome

(2008) V. E. Velculescu   CARCINOGENESIS

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

(2008) Jeffrey A Engelman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY

Translating insights from the cancer genome into clinical practice

(2008) Lynda Chin et al.   NATURE

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

(2007) Lecia V. Sequist et al.   Annual Review of Medicine